Examples of dose adjustments based on PGDx

The influence of genetic polymorphisms in cytochrome P450 enzymes CYP2D6, CYP2C19 and CYP2C9, thiopurine S-methyltransferase (TPMT), and N-acetyltransferase type 2 (NAT2) is expressed as subpopulation-specific dosages, according to the difference in pharmacokinetic parameters from clinical studies. The dose adjustments illustrated by the bars in this graph are based on differences in dose-related pharmacokinetic parameters (clearance, AUC, STEADY STATE CONCENTRATION) caused by particular genotypes and are calculated using the methods described earlier. Substantial adjustments need to be made to the drug dose to achieve the same level of drug exposure in individuals with different genotypes.